SK pharmteco, a worldwide company that provides development, manufacturing, and analytical testing services for small molecule and cell & gene therapy industries, has formed a partnership with Rznomics Inc., a biopharmaceutical company from South Korea that focuses on RNA-based gene therapeutics, by signing an MOU for a development and manufacturing contract.

The long-term agreement will create a strategic partnership between SK pharmteco and Rznomics for the development and sale of various gene therapy products. SK pharmteco will offer its technical knowledge and resources, such as facilities and staff, to facilitate the transition from clinical to full-scale commercial production of Rznomics' RNA-based biopharmaceuticals.

"We are thrilled about the opportunity to partner with Rznomics on their groundbreaking initiatives," said Andy Fenny, CFO of SK pharmteco. "By combining our significant expertise in gene therapy manufacturing with Rznomics' innovative RNA-based therapeutic approach, we believe this collaboration has the potential to deliver life-changing treatments to patients in need quickly."   Seong-Wook Lee, President and CEO of Rznomics, commented: "This partnership will mark late-stage development and manufacturing of our gene therapy pipeline to prepare the path towards Phase II and later stage clinical trials and potential commercialization. We look forward to working closely with SK pharmteco."